ACAD
ACADIA PHARMACEUTICALS INC
Key Financials
Net Income
$391.0M
↑ 72.7%
Gross Profit
$684.8M
↑ 221.3%
Operating Income
$104.8M
↓ 54.6%
Revenue
$1.1B
↑ 11.9%
EPS (Diluted)
$2.30
↑ 69.1%
Cash & Equivalents
$177.7M
↓ 44.4%
Shareholders' Equity
$1.2B
↑ 67.5%
Total Liabilities
$336.8M
↓ 26.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/20/2026 | View on SEC |
| 3 | 3/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ACAD |
| Company Name | ACADIA PHARMACEUTICALS INC |
| CIK | 1070494 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-558-2871 |